Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. (27th January 2021)

• Record Type: Journal Article
• Authors: Krause, Peter J; Auwaerter, Paul G; Bannuru, Raveendhara R; Branda, John A; Falck-Ytter, Yngve T; Lantos, Paul M; Lavergne, Valéry; Meissner, H Cody; Osani, Mikala C; Rips, Jane Glazer; Sood, Sunil K; Vannier, Edouard; Vaysbrot, Elizaveta E; Wormser, Gary P
• Is Part Of: Clinical infectious diseases. Volume 72:Number 2(2021)
• Page Start: 185
• Page End: 189
• Publication Date: 2021-01-27
• Subjects: Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab050
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: The purpose of this guideline is to provide evidence-based guidance for the most effective strategies for the diagnosis and management of babesiosis. The diagnosis and treatment of co-infection with babesiosis and Lyme disease will be addressed in a separate Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) guideline [1 ]. Recommendations for the diagnosis and treatment of human granulocytic anaplasmosis can be found in the recent rickettsial disease guideline developed by the Centers for Disease Control and Prevention [2 ]. The target audience for the babesiosis guideline includes primary care physicians and specialists caring for this condition, such as infectious diseases specialists, emergency physicians, intensivists, internists, pediatricians, hematologists, and transfusion medicine specialists.